Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 116

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 116
---
 Principal obligations on the debt arrangements |     | $     | 150,000 |     | $                      |       - |     | $         |  3,089 |     | $         |  6,757 |     | $           | 140,154 |
| Interest obligations on the debt arrangements  |     |       | 106,312 |     |                        |   8,772 |     |           | 14,455 |     |           | 10,787 |     |             |  72,298 |
| Purchase obligations                           |     |       | 677,617 |     |                        | 677,617 |     |           |      - |     |           |      - |     |             |       - |
| Total                                          |     | $     | 933,929 |     | $                      | 686,389 |     | $         | 17,544 |     | $         | 17,544 |     | $           | 212,452 |

65 Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the achievement of certain milestones. These contingent milestones may or may not be achieved. We have not included any of these amounts in the table above as we cannot estimate or predict when, or if, these amounts will become due. Components of Results of Operations Product Revenues - net of Discounts and Rebates To date, we have received the majority of our product revenues from sales of our Arakoda product to the US Department of Defense (the “DoD”) and resellers in the U.S. and abroad. Foreign sales to both Australia and Europe are further subject to profit sharing agreements for boxes sold to customers. Currently, the procurement contract with the DoD has expired and DoD sales last occurred in 2021. Sales to resellers in the US are subject to considerable discounts and rebates for services provided by our third-party logistics (“3PL”) partner and wholesalers and pharmacy benefit managers (“PBMs”). Cost of Revenues, Gross Profit (Loss), and Gross Margin Cost of revenues associated with our products is primarily comprised of direct materials, manufacturing related costs incurred in the production process and inventory write-downs due to expiration. Other Operating Revenues Other operating revenues for the periods presented primarily consist of research revenue earned from the Australian Tax Authority for research activities conducted in Australia. Beginning in the third quarter of 2024, we began to recognize research revenues associated with the new contract with the United States Army Medical